CAS No. : 1818885-28-7
|Size||Stock||Price||Quantity||Add to Cart||Quotation Online|
|Cat. No. :||CS-4776|
|CAS No. :||1818885-28-7|
|M. Wt. :||923.43|
|Solubility:||10 mM in DMSO|
ARV-825 is a BRD4 Inhibitor based on PROTAC technology. ARV-825 shows affinity to BD1 and BD2 of BRD4 with Kds of 90 and 28 nM, respectively. IC50 & Target: Kd: 90 nM (Bromodomain 1 of BRD4), 28 nM (Bromodomain 2 of BRD4) In Vitro: ARV-825 is a hetero-bifunctional proteolysis-targeting chimera (PROTAC) that recruits BRD4 to the E3 ubiquitin ligase cereblon. ARV-825 actively recruits BRD4 to cereblon, resulting in the rapid and efficient degradation of the former via the proteasome. Given that BRD4 and cereblon binding moieties in ARV-825 have Kds of 28-90 nM and ~3 µM to their respective targets, this suggests that ARV-825 acts in a substoichiometric way in mediating BRD4 degradation. ARV-825 treatment results in prolonged BRD4 down-regulation and downstream signaling suppression compared to BRD4 inhibitors.
Protocol:Kinase Assay: Affinity of compounds (e.g., ARV-825) with Bromodomain 1 and 2 of BRD4 is determined with BROMOscan by DiscoverX.
Lu J, et al. Hijacking the E3 Ubiquitin Ligase Cereblon to Efficiently Target BRD4. Chem Biol. 2015 Jun 18;22(6):755-63.
- Select Batch :
- CS-4776 20243
|Tags:ARV-825 supplier,ARV-825 purchase,ARV-825 manufacturer,ARV-825 sigma,ARV-825 distributor,cost,ARV-825 buy,ARV-825 for sale|